Hanall Biopharma Net Asset Quality Index
Hanall Biopharma net asset quality index. Hanall Biopharma (009420) has a Net Asset Quality Index of 78.1% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ₩201.82 Billion minus total liabilities of ₩44.17 Billion yields net assets of ₩157.65 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check Hanall Biopharma earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hanall Biopharma (2011–2024)
Net asset quality index of Hanall Biopharma from 2011 to 2024. This chart shows how Hanall Biopharma's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 78.1%, representing net assets of ₩157.65 Billion against total assets of ₩201.82 Billion KRW. See net assets of Hanall Biopharma for net asset value and shareholders' equity analysis.
Hanall Biopharma Net Asset Quality Index by Year (2011–2024)
Hanall Biopharma net asset quality index by year from 2011 to 2024. The table below presents the year-by-year Net Asset Quality Index for Hanall Biopharma from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 009420 market cap overview.
| Year | Quality Index | Net Assets (KRW) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 79.1% | ₩168.35 Billion | ₩212.88 Billion | ₩44.53 Billion | ▲ +1.4 pp |
| 2023 | 77.7% | ₩186.22 Billion | ₩239.75 Billion | ₩53.53 Billion | ▼ -1.2 pp |
| 2022 | 78.8% | ₩168.26 Billion | ₩213.45 Billion | ₩45.19 Billion | ▼ -3.5 pp |
| 2021 | 82.4% | ₩163.49 Billion | ₩198.48 Billion | ₩34.99 Billion | ▲ +0.0 pp |
| 2020 | 82.3% | ₩181.27 Billion | ₩220.13 Billion | ₩38.86 Billion | ▲ +9.0 pp |
| 2019 | 73.4% | ₩140.42 Billion | ₩191.38 Billion | ₩50.97 Billion | ▲ +1.3 pp |
| 2018 | 72.0% | ₩116.92 Billion | ₩162.30 Billion | ₩45.39 Billion | ▲ +6.1 pp |
| 2017 | 65.9% | ₩111.20 Billion | ₩168.70 Billion | ₩57.50 Billion | ▼ -17.7 pp |
| 2016 | 83.7% | ₩104.36 Billion | ₩124.73 Billion | ₩20.37 Billion | ▲ +2.4 pp |
| 2015 | 81.3% | ₩95.22 Billion | ₩117.13 Billion | ₩21.91 Billion | ▲ +28.7 pp |
| 2014 | 52.6% | ₩45.81 Billion | ₩87.17 Billion | ₩41.36 Billion | ▼ -8.4 pp |
| 2013 | 60.9% | ₩59.63 Billion | ₩97.85 Billion | ₩38.23 Billion | ▼ -2.4 pp |
| 2012 | 63.3% | ₩78.67 Billion | ₩124.27 Billion | ₩45.60 Billion | ▲ +15.2 pp |
| 2011 | 48.1% | ₩50.70 Billion | ₩105.46 Billion | ₩54.75 Billion | — |